ORGO icon

Organogenesis Holdings

4.35 USD
+0.07
1.64%
At close Apr 2, 4:00 PM EDT
After hours
4.24
-0.11
2.53%
1 day
1.64%
5 days
-7.05%
1 month
-19.59%
3 months
43.56%
6 months
52.63%
Year to date
43.56%
1 year
66.67%
5 years
46.46%
10 years
-55.38%
 

About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Employees: 869

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

469% more call options, than puts

Call options by funds: $74K | Put options by funds: $13K

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

11% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 36

10% more capital invested

Capital invested by funds: $182M [Q3] → $200M (+$18M) [Q4]

7% more funds holding

Funds holding: 111 [Q3] → 119 (+8) [Q4]

1.74% more ownership

Funds ownership: 48.06% [Q3] → 49.8% (+1.74%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
38%
upside
Avg. target
$6
38%
upside
High target
$6
38%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Morgan Stanley
Drew Ranieri
25% 1-year accuracy
2 / 8 met price target
38%upside
$6
Equal-Weight
Maintained
5 Mar 2025

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby.
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024.
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th.
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
Neutral
GlobeNewsWire
4 months ago
Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
Organogenesis Expands Manufacturing Capacity to Support Future Growth
Neutral
GlobeNewsWire
4 months ago
Organogenesis Commends Final LCDs
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination
Organogenesis Commends Final LCDs
Neutral
Seeking Alpha
4 months ago
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode.
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
4 months ago
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Organogenesis (ORGO) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
4 months ago
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Neutral
GlobeNewsWire
4 months ago
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Neutral
GlobeNewsWire
5 months ago
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
Charts implemented using Lightweight Charts™